Tag: ILLUMENATE

Late-breaking ILLUMENATE data demonstrate three-year safety and efficacy for Stellarex DCB

Three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE European randomised controlled trial (EU RCT) have been presented in a late-breaking trial session...

Two-year ILLUMENATE Global data find 72.4% primary patency with Stellarex DCB

After two years of follow-up, the ILLUMENATE Global study has confirmed the durability of the Stellarex drug-coated balloon (Spectranetics/Philips) with primary patency rates comparable...

Two-year efficacy of Philips’ Stellarex 0.035” low-dose drug-coated balloon demonstrated

Philips has announced the two-year results from the ILLUMENATE European randomised clinical trial (EU RCT) demonstrating the efficacy of the Philips Spectranetics’ Stellarex 0.035”...

Spectranetics announces FDA approval of Stellarex drug-coated balloon

Spectranetics has announced receipt of US Food and Drug Administration (FDA) pre-market approval of the Stellarex drug-coated balloon (DCB), designed to restore and maintain blood flow...

Global cohorts report drug-coated balloon success above the knee and “promising”...

Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...

Combined 12-month analysis of ILLUMENATE EU and US trials presented at...

At LINC 2017 (24–27 January, Leipzig, Germany), Sean Lyden (Cleveland Clinic, Cleveland, USA) presented an update on the 12-month results of the European and...

Positive results for Spectranetics Stellarex demonstrated in ILLUMENATE 12-month data

The final 12-month results of the Stellarex (Spectranetics) drug-coated balloon ILLUMENATE Global Study have found high primary patency and freedom from clinically driven target...

Spectranetics files FDA pre-market approval application for the Stellarex drug-coated balloon

Spectranetics has submitted its pre-market approval application for the Stellarex drug-coated angioplasty balloon to the US Food and Drug Administration (FDA). Stellarex is designed to restore...

First randomised Stellarex DCB data show 12-month outcomes superior to percutaneous...

Marianne Brodmann of Medical University Graz, Austria, has presented the final 12-month results of the Stellarex (Spectranetics) ILLUMENATE drug-coated balloon European randomised clinical trial...